HHT | sciencenewsnet.in

Breaking News

MD Anderson Research Highlights: ASH 2024 Special Edition

Embargoed Autism Study in Journal Nature: Virtual Press Briefing

Research reveals how fructose in diet enhances tumor growth

Researchers Discover An Origin of Idiopathic Autism

Psychological Reactance to Anti-Piracy Messages explained by Gender and Attitudes

Hybrid Entrepreneurship and Entrepreneurs’ Well-Being: The Moderating Effect of Role Demands Outside Entrepreneurship

The more, the better: The influence of overconfident CEOs on their firms’ digital orientation

MSK Awards and Appointments November 2024

When people make the difference: A person-organization fit approach in knowledge transfer offices

BGSU leads first-of-its-kind global UNESCO study on the motivations, ethical standards of digital content creators

05 Dec, 2024

Cleveland Clinic Study Is First to Show Success in Treating Rare Blood Disorder

September 18, 2024 sarah JonasResearch Results

CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide.